Vlajinac Hristina, Sipetić-Grujicić Sandra, Janković Slavenka, Marinković Jelena, Kocev Nikola, Marković-Denić Ljiljana, Bjegović Vesna
Institute of Epidemiology, University of Belgrade, School of Medicine, Belgrade, Serbia and Montenegro.
Croat Med J. 2006 Feb;47(1):134-41.
To provide a comprehensive assessment of burden of selected cancers in Serbia.
We calculated disability adjusted life years (DALY)-- the sum of the years of life lost (YLL) from premature mortality and the years lived with disability (YLD)--for cancers of stomach, colon and rectum, lung, breast, and cervical cancer for central Serbia and Vojvodina, Serbia and Montenegro. The obtained values were compared with the corresponding values for European region as estimated by the World Health Organization. The study was conducted between October 2002 and September 2003. The cancer burden was estimated for the year 2000.
Observed cancers were responsible for 133,689 DALYs (73,197 for men and 60,482 for women). There were significantly more losses because of premature death than disease disability (95.2% vs 4.8% in men P<0.001, and 93.2% vs 6.8% in females, P<0.001). The cancer burden was dominated by lung cancer in men and breast cancer in women. The cancer burden was very small before the age of 35.
DALYs per 1000 population were higher in Serbia than in the European region for all observed cancers except for stomach cancer. The participation of a burden caused by disability in the total burden of selected cancers was lower in Serbia than in other European countries, with the greatest differences in colorectal, breast, and cervical cancers.
全面评估塞尔维亚特定癌症的负担。
我们计算了塞尔维亚中部以及塞尔维亚和黑山的伏伊伏丁那地区胃癌、结肠癌、直肠癌、肺癌、乳腺癌和宫颈癌的伤残调整生命年（DALY），即过早死亡导致的生命年损失（YLL）与残疾生存年数（YLD）之和。将所得值与世界卫生组织估计的欧洲区域相应值进行比较。该研究于2002年10月至2003年9月进行。对2000年的癌症负担进行了估计。
观察到的癌症导致133,689个伤残调整生命年（男性为73,197个，女性为60,482个）。因过早死亡造成的损失显著多于疾病残疾造成的损失（男性中分别为95.2%对4.8%，P<0.001；女性中分别为93.2%对6.8%，P<0.001）。男性的癌症负担以肺癌为主，女性以乳腺癌为主。35岁之前癌症负担非常小。
除胃癌外，塞尔维亚所有观察到的癌症每1000人口的伤残调整生命年均高于欧洲区域。塞尔维亚特定癌症总负担中残疾所致负担的占比低于其他欧洲国家，在结直肠癌、乳腺癌和宫颈癌方面差异最大。
